Nordic symposium on "toxicology and pharmacology without animal experiments-Will it be possible in the next 10 years?"

Research output: Contribution to journalReviewResearchpeer-review

Standard

Nordic symposium on "toxicology and pharmacology without animal experiments-Will it be possible in the next 10 years?". / Knudsen, Lisbeth E; Smith, Adrian; Törnqvist, Elin; Forsby, Anna; Tähti, Hanna.

In: Basic & Clinical Pharmacology & Toxicology, Vol. 124, No. 5, 2019, p. 560-567.

Research output: Contribution to journalReviewResearchpeer-review

Harvard

Knudsen, LE, Smith, A, Törnqvist, E, Forsby, A & Tähti, H 2019, 'Nordic symposium on "toxicology and pharmacology without animal experiments-Will it be possible in the next 10 years?"', Basic & Clinical Pharmacology & Toxicology, vol. 124, no. 5, pp. 560-567. https://doi.org/10.1111/bcpt.13193

APA

Knudsen, L. E., Smith, A., Törnqvist, E., Forsby, A., & Tähti, H. (2019). Nordic symposium on "toxicology and pharmacology without animal experiments-Will it be possible in the next 10 years?". Basic & Clinical Pharmacology & Toxicology, 124(5), 560-567. https://doi.org/10.1111/bcpt.13193

Vancouver

Knudsen LE, Smith A, Törnqvist E, Forsby A, Tähti H. Nordic symposium on "toxicology and pharmacology without animal experiments-Will it be possible in the next 10 years?". Basic & Clinical Pharmacology & Toxicology. 2019;124(5):560-567. https://doi.org/10.1111/bcpt.13193

Author

Knudsen, Lisbeth E ; Smith, Adrian ; Törnqvist, Elin ; Forsby, Anna ; Tähti, Hanna. / Nordic symposium on "toxicology and pharmacology without animal experiments-Will it be possible in the next 10 years?". In: Basic & Clinical Pharmacology & Toxicology. 2019 ; Vol. 124, No. 5. pp. 560-567.

Bibtex

@article{859e1fceff524338998ba01e7116b8a7,
title = "Nordic symposium on {"}toxicology and pharmacology without animal experiments-Will it be possible in the next 10 years?{"}",
abstract = "Toxicological and pharmacological information from human cells and tissues provides knowledge readily applicable to human safety assessment and to the efficacy assessment of pharmaceuticals. The 3R principle in animal studies includes the use of human material in the R of Replacement. The Reduction and Refinement Rs are related to animal use. Knowledge of the 3Rs and successful 3R methods are a prerequisite for the Reduction of animal experiments in the future. More collaboration among researchers using experimental animals and those working in vitro is necessary with mutual respect. The OECD Guidelines for the Testing of Chemicals have included the animal-free part of the 3Rs in guidances for the development and reporting of Adverse Outcome Pathways (AOPs), which is to be part of the Integrated Approaches to Testing and Assessment (IATA). The 3R centres established to help fulfil the Directive 2010/63/EU play an important role to promote the 3Rs and in the development of animal-free toxicology. Research centres in each Nordic country are founded upon solid research activities in cell and organ toxicity, including major EU programmes to promote 3Rs and implementation of good practices and methods broadly in all stakeholders of industry, regulators and academia. In the light of this, the Nordic Symposium on Toxicology and Pharmacology without Animal Experiments addressed more adopted/modified test guidelines or new test guidelines for new end-points, or hazard challenges, new in vitro 3D models, speeding up transfer of knowledge from research to regulation to understand AOP and towards IATA.",
author = "Knudsen, {Lisbeth E} and Adrian Smith and Elin T{\"o}rnqvist and Anna Forsby and Hanna T{\"a}hti",
note = "{\circledC} 2018 Nordic Association for the Publication of BCPT (former Nordic Pharmacological Society).",
year = "2019",
doi = "10.1111/bcpt.13193",
language = "English",
volume = "124",
pages = "560--567",
journal = "Basic & Clinical Pharmacology & Toxicology",
issn = "1742-7835",
publisher = "Wiley-Blackwell",
number = "5",

}

RIS

TY - JOUR

T1 - Nordic symposium on "toxicology and pharmacology without animal experiments-Will it be possible in the next 10 years?"

AU - Knudsen, Lisbeth E

AU - Smith, Adrian

AU - Törnqvist, Elin

AU - Forsby, Anna

AU - Tähti, Hanna

N1 - © 2018 Nordic Association for the Publication of BCPT (former Nordic Pharmacological Society).

PY - 2019

Y1 - 2019

N2 - Toxicological and pharmacological information from human cells and tissues provides knowledge readily applicable to human safety assessment and to the efficacy assessment of pharmaceuticals. The 3R principle in animal studies includes the use of human material in the R of Replacement. The Reduction and Refinement Rs are related to animal use. Knowledge of the 3Rs and successful 3R methods are a prerequisite for the Reduction of animal experiments in the future. More collaboration among researchers using experimental animals and those working in vitro is necessary with mutual respect. The OECD Guidelines for the Testing of Chemicals have included the animal-free part of the 3Rs in guidances for the development and reporting of Adverse Outcome Pathways (AOPs), which is to be part of the Integrated Approaches to Testing and Assessment (IATA). The 3R centres established to help fulfil the Directive 2010/63/EU play an important role to promote the 3Rs and in the development of animal-free toxicology. Research centres in each Nordic country are founded upon solid research activities in cell and organ toxicity, including major EU programmes to promote 3Rs and implementation of good practices and methods broadly in all stakeholders of industry, regulators and academia. In the light of this, the Nordic Symposium on Toxicology and Pharmacology without Animal Experiments addressed more adopted/modified test guidelines or new test guidelines for new end-points, or hazard challenges, new in vitro 3D models, speeding up transfer of knowledge from research to regulation to understand AOP and towards IATA.

AB - Toxicological and pharmacological information from human cells and tissues provides knowledge readily applicable to human safety assessment and to the efficacy assessment of pharmaceuticals. The 3R principle in animal studies includes the use of human material in the R of Replacement. The Reduction and Refinement Rs are related to animal use. Knowledge of the 3Rs and successful 3R methods are a prerequisite for the Reduction of animal experiments in the future. More collaboration among researchers using experimental animals and those working in vitro is necessary with mutual respect. The OECD Guidelines for the Testing of Chemicals have included the animal-free part of the 3Rs in guidances for the development and reporting of Adverse Outcome Pathways (AOPs), which is to be part of the Integrated Approaches to Testing and Assessment (IATA). The 3R centres established to help fulfil the Directive 2010/63/EU play an important role to promote the 3Rs and in the development of animal-free toxicology. Research centres in each Nordic country are founded upon solid research activities in cell and organ toxicity, including major EU programmes to promote 3Rs and implementation of good practices and methods broadly in all stakeholders of industry, regulators and academia. In the light of this, the Nordic Symposium on Toxicology and Pharmacology without Animal Experiments addressed more adopted/modified test guidelines or new test guidelines for new end-points, or hazard challenges, new in vitro 3D models, speeding up transfer of knowledge from research to regulation to understand AOP and towards IATA.

U2 - 10.1111/bcpt.13193

DO - 10.1111/bcpt.13193

M3 - Review

VL - 124

SP - 560

EP - 567

JO - Basic & Clinical Pharmacology & Toxicology

JF - Basic & Clinical Pharmacology & Toxicology

SN - 1742-7835

IS - 5

ER -

ID: 215131987